首页> 外国专利> (3-(4-(Pyridin-2-ylamino)-butyryl)-2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluoren-9-yl)-acetic acid derivatives and related tricyclic indanyls as alphaVbeta3 and alphaVbeta5 integrin inhibitors for the treatment of cancer and unstable angina

(3-(4-(Pyridin-2-ylamino)-butyryl)-2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluoren-9-yl)-acetic acid derivatives and related tricyclic indanyls as alphaVbeta3 and alphaVbeta5 integrin inhibitors for the treatment of cancer and unstable angina

机译:(3-(4-(吡啶-2-基氨基)-丁酰基)-2,3,4,4a,9,9a-六氢-1H-3-氮杂-芴-9-基)-乙酸衍生物和相关的三环茚满为AlphaVbeta3和AlphaVbeta5整合素抑制剂,用于治疗癌症和不稳定型心绞痛

摘要

The present invention is directed to substituted indanyl compounds of Formula (I): useful for treating integrin-mediated disorders such as, but not limited to unstable angina, thromboemboic disorders, osteoporosis, growth and metastasis of malignant tumors, diabetic retinopathy, arthritis, viral disease and surgical adhesions.The substituents are defined in claim 1.
机译:本发明涉及式(I)的取代的茚满基化合物: <图像文件=“ IMGA0001.GIF” he =“ 40” imgContent =“ chem” imgFormat =“ GIF” wi =“ 75” /> 可用于治疗整合素介导的疾病例如但不限于不稳定型心绞痛,血栓栓塞性疾病,骨质疏松,恶性肿瘤的生长和转移,糖尿病性视网膜病,关节炎,病毒性疾病和手术粘连。取代基在权利要求1中定义。

著录项

  • 公开/公告号EP1506779A1

    专利类型

  • 公开/公告日2005-02-16

    原文格式PDF

  • 申请/专利权人 JANSSEN PHARMACEUTICA N.V.;

    申请/专利号EP20040254584

  • 申请日2004-07-30

  • 分类号A61K31/435;A61K31/506;A61K31/4375;A61K31/444;C07D401/12;C07D471/04;A61P9/10;A61P35/04;

  • 国家 EP

  • 入库时间 2022-08-21 22:08:14

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号